Argenx
ARGXARGX · Stock Price
Historical price data
Overview
Argenx is a mission-driven immunology company dedicated to improving the lives of patients with severe autoimmune diseases through innovative antibody therapies. Its core achievement is the successful global commercialization of efgartigimod (VYVGART®), a first-in-class FcRn blocker, establishing a commercial foundation and validating its platform. The company's strategy centers on expanding efgartigimod's label into multiple autoimmune indications while advancing a broad, deep pipeline of novel candidates from its proprietary SIMPLE Antibody™ platform, aiming to build a leading, fully integrated immunology franchise.
Technology Platform
The SIMPLE Antibody™ platform is an integrated antibody engineering ecosystem used to create humanized antibodies with enhanced therapeutic profiles, forming the foundation for its FcRn antagonist and complement inhibitor franchises.
Pipeline
78| Drug | Indication | Stage | Watch |
|---|---|---|---|
| IV efgartigimod | Myasthenia Gravis Crisis | Approved | |
| Efgartigimod | Myasthenia Gravis Crisis | Approved | |
| Efgartigimod PH20 SC | New Onset Generalized Myasthenia Gravis (gMG) | Approved | |
| Efgartigimod PH20 SC | Chronic Inflammatory Demyelinating Polyneuropathy | Approved | |
| Efgartigimod IV | Generalized Myasthenia Gravis | Phase 3 |
Funding History
4FDA Approved Drugs
2
Company Timeline
Founded in Ghent, Netherlands
Series B: $39.0M
IPO — $100.0M
Series C: $75.0M
FDA Approval: VYVGART
FDA Approval: VYVGART HYTRULO